There are 398 resources available
156TiP - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer.
Presenter: Bethany Torr
Session: Poster Display session
157P - Adoptive cell therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2 expressing breast cancer
Presenter: Annavera Ventura
Session: Poster Display session
158P - Predictors of Response to Neoadjuvant Checkpoint Inhibition with chemotherapy in Triple-Negative Breast Cancer (TNBC): A Meta-analysis of Randomized Control Trials (RCTs)
Presenter: Arya Mariam Roy
Session: Poster Display session
159P - Q-TWiST Analysis of Pembrolizumab Combined with Chemotherapy as First Line Treatment of Metastatic TNBC that Expresses PD-L1
Presenter: Peter A. Fasching
Session: Poster Display session
160TiP - A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2 negative breast cancer: JCOG1919E/AMBITION study
Presenter: Fumikata Hara
Session: Poster Display session
168P - Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the Phase 3 ASCENT study
Presenter: Veronique Dieras
Session: Poster Display session
169P - Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis
Presenter: Hope Rugo
Session: Poster Display session
170P - Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
Presenter: Kerstin Riecke
Session: Poster Display session
171P - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
Presenter: Frederik Marmé
Session: Poster Display session
172P - Long-term follow-up of randomized controlled trial (RCT) of locoregional treatment versus not of the primary tumour in de-novo metastatic breast cancer
Presenter: Nita Nair
Session: Poster Display session